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A large body of data shows that Natural Killer (NK) cells are immune effectors exerting
a potent cytolytic activity against tumors and virus infected cells. The discovery and
characterization of several inhibitory and activating receptors unveiled most of the
mechanisms allowing NK cells to spare healthy cells while selectively attacking abnormal
tissues. Nevertheless, the mechanisms ruling NK cell subset recirculation among the
different compartments of human body have only lately started to be investigated. This
is particularly true for pathological settings such as tumors or infected tissues but also
for para-physiological condition like pregnant human uterine mucosa. It is becoming
evident that the microenvironment associated to a particular clinical condition can deeply
influence the migratory capabilities of NK cells. In this review we describe the main
mechanisms and stimuli known to regulate the expression of chemokine receptors and
other molecules involved in NK cell homing to either normal or pathological/inflamed
tissues, including tumors or organs such as lung and liver. We will also discuss the role
played by the chemokine/chemokine receptor axes in the orchestration of physiological
events such as NK cell differentiation, lymphoid organ retention/egress and recruitment
to decidua during pregnancy.
Keywords: natural killer cells, chemokines and chemokine receptors, migration and residency, tumor and
inflammation, pregnancy
INTRODUCTION
The initial view describing Natural Killer (NK) cells as a quite homogeneous CD3neg CD56+
circulating lymphocyte population has been largely overcome. NK cells have been recently
included in a wider innate lymphoid cell (ILC) family, and circulating cells are just the tip of
an iceberg formed by a conspicuous and heterogeneous lymphoid population colonizing both,
lymphoid and non lymphoid tissues (1–3). Moreover, cytometry by time-of-flight (CyTOF)
highlighted the existence in peripheral blood (PB) of a single individual of at least 30,000
different NK cell phenotypes (4). These findings consolidate the concept that observed phenotypic
and functional NK cell status actually represents a single crystalized picture of a very dynamic
process. Nevertheless, in healthy individuals, two main circulating PB NK cell populations have
been extensively studied, CD56bright and CD56dim NK cells, which represent sequential stages of
maturation and show a dichotomy in phenotypic and functional properties (5). These include the
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expression of MHC class I-specific inhibitory Killer Ig-like
Receptors (KIRs), restricted to CD56dim NK cells that represent
the majority of cells circulating in blood. KIRs are involved in
NK cell “education,” a phenomenon that provides the basis of
self-tolerance and generates “armed” cells, i.e., NK cells fully
responsive to the engagement of activating receptors (i.e., NCR,
NKG2D, and DNAM-1) (6, 7). CD56dim NK cells also express
high levels of CD16, thus exerting strong antibody-dependent
cellular cytotoxicity (ADCC). Moreover, they efficiently respond
to cytokines stimulation and are characterized by a chemokine
receptor repertoire giving them the potential to colonize
lymphoid and non-lymphoid tissues in response to a proper
chemokine milieu.
The composition of the milieu can greatly vary in perturbed
tissues. This justifies the prevalence in some tumors of immature,
poor cytolytic CD56bright NK cells that are undetectable in
matched healthy tissues (8). Tumor parenchyma, as well as
the immune cells participating to the inflammatory processes,
may change the microenvironment providing NK cells with a
plethora of stimuli. These include membrane-bound or soluble
molecules such as chemokines or cytokines (TGF-β, IL-12, IL-
18), which either promote or dampen innate and adaptive
immune responses. Cytokines, in addition to shape the functional
activity of NK cells, modify their chemokine receptor repertoire
altering their native migratory potential (9–13) and at the same
time provide signals essential to generate, expand and recall
memory NK cell populations (14). Interestingly, recent data
showed that non-hematopoietic organs such as liver can be
colonized by peculiar tissue resident NK cell populations that
belong to the memory NK cell reservoir able to mediate "recall”
responses (15).
Here, we will recapitulate studies that analyzed the main
mechanisms regulating NK cell trafficking in lymphoid and
non-lymphoid tissue under either steady state or “perturbed”
conditions, including tumors, inflammation and pregnancy.
DEFINING DYNAMICS OF NK CELLS IN
HEALTHY TISSUES
NK cells are not exclusively found in PB but populate different
tissues and organs. The traditional view of NK cells as “armed”
effector cells, which patrol human body through blood ready to
extravasate to the site of injury, has been partially revisited and a
growing number of studies show that NK cells might also stably
reside in most peripheral tissues, under steady-state conditions.
Until recently, the task of depicting NK cell distribution in
human compartments has suffered from several methodological
shortcomings. Earlier analyses often relied on the use for NK cells
detection of markers poorly specific and/or unable to distinguish
the two main NK cell subsets, i.e., CD56bright CD16low/neg
Perflow and CD56dim CD16pos Perfhigh. The advent of new
OMICS technologies, and the possibility to perform single-cell
analyses have expanded our understanding on the distribution
of NK cells across human body. Indeed, in the recent years, our
knowledge about NK cell diversity has further increased with the
identification of NK cell subsets specifically populating various
peripheral solid organs, such as lung, liver, lymphoid tissues, and
uterus. These findings have challenged the classical view of NK
cells as a lineage comprising a relatively homogeneous population
of cells with similar functions and longevity. Nonetheless, at
variance with B and T cells, we know little about recirculation
and trafficking of NK cells across peripheral tissues. AlthoughNK
cells express an ample array of chemotactic receptors, the role of
the different chemokines in guiding in vivo the distribution of NK
cells through the body compartments still remains unclear. The
distribution of NK cells seems to be subset-specific in mouse, as
different NK cell subsets showed organ-specific localizations (16).
Conversely, this issue has been poorly investigated in the human
system. As the twomajor PB-NK cell subsets display a chemokine
receptors pattern that only partially overlaps, they may have
a peculiar tissue-specific compartmentalization (Figure 1). PB-
CD56bright NK cells are uniquely characterized by the expression
of CCR7, CXCR3, and L-selectin (CD62L), which justify their
abundance in secondary lymphoid tissues (SLTs). Conversely,
PB-CD56dim NK cells, despite sharing the CXCR4 receptor with
CD56bright NK cells, are equipped with receptors specific for
inflammatory chemokines, such as CXCR1, CXCR2, CX3CR1 (8,
16, 17). Additionally, CD56dim NK cells can migrate in response
to factors that do not belong to the chemokine superfamily.
These include the proinflammatory protein chemerin and the
sphingosine 1-phosphate (S1P) molecule that affect trafficking
of NK cells during inflammation or steady-state conditions,
respectively (18, 19). Based on the different expression of
chemotactic receptors, the tissue distribution of human NK cell
subsets observed under steady-state conditions is dependent on
the expression of local tissue-specific environmental signals. In
order to shed light on themechanisms lying behind themigratory
properties of PB NK cells, a wide array of samples derived from
different body compartments was analyzed to investigate the
presence and distribution of functionally different NK cell subsets
(8). The study showed that the relative distribution of CD56bright
and CD56dim NK subsets in the various human districts does not
parallel that in PB. CD56dim NK cells represent the major NK cell
subset in bone marrow (BM), lung, spleen, subcutaneous adipose
tissue and breast tissue, whereas CD56bright NK cells abundantly
outnumber cytotoxic NK cells in gastric and intestinal mucosa
associated lymphoid tissues (MALTs), liver, uterus, visceral
adipose tissue, adrenal gland, and kidney (8, 20, 21). Importantly,
the relative distribution of the two main NK cell subsets matched
with the specific patterns of chemotactic factors expressed in the
tissues (8).
A main question arising from the detection of NK cells
in many organs is whether NK cells stably reside in those
tissues or could eventually exit and recirculate. Studying the
dynamics of NK cells under steady-state conditions is limited
by the difficulty of having access to samples from human body
districts. On this regard, useful hints may be derived from studies
in which human subjects have been treated with monoclonal
antibodies directed against molecules pivotal in lymphocytes
migration, such as integrins. This is the case of natalizumab,
a humanized monoclonal antibody directed against the α4-
chain of VLA-4 (α4β1) and α4β7 integrins, widely expressed
on many different lymphocyte populations including T cells,
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FIGURE 1 | Circulating and tissues resident NK cells. (A) In human two main NK cell subsets, CD56bright and CD56dim, can be detected in peripheral blood (PB NK)
having a different repertoire of chemokine receptors. Tissue resident (tr) NK cells share the expression of certain markers but express molecules typical of the hosting
tissue.(B) large numbers of NK cells populate the decidua, particularly in the first trimester of pregnancy. Decidual NK cells have unique phenotypic and functional
characteristics, which contribute to support nutrition of the fetus, ensure maternal-fetal tolerance and control viral infections. Prf1, perforin; KIRs, killer cell
immunoglobulin-like receptors; SLT, secondary lymphoid tissues.
B cells, and NK cells as well as on a majority of monocytes
and macrophages. Interestingly, it has been reported that 1-
year treatment with natalizumab in multiple sclerosis patients
resulted in a pronounced accumulation (almost 2-fold increase
compared to baseline levels) of NK cells in PB (22), which
then gradually decreased upon treatment interruption (23).
These data are in evident agreement with a dynamic passage of
circulating NK cells across the endothelial barriers for patrolling
peripheral tissues, although it remains to be determined whether
it might occur also in steady-state or just under inflammatory
conditions.
In addition to extravasation from PB to solid tissues, NK
cells may eventually egress from peripheral tissues and trafficking
to SLT. This re-circulation has been suggested by the direct
investigation of afferent lymph draining from normal skin
(24) and analysis of cellular content in seroma fluid upon
axillary lymph nodes (LN) dissection, which represents an
accumulation of bona fide afferent lymph (25, 26). Interestingly,
most seroma NK cells expressed high level of CCR7 and
CD62L, as well as CXCR4, CXCR3, a chemokine receptor
repertoire identifying lymphocyte populations migrating toward
SLTs. These data indicate that high endothelial venules (HEVs)
might not represent the only route for NK cell entrance in
SLTs. Conversely, very little information is available regarding
the egress of NK cells from SLTs. It has been described in the
murine model that changes in responsiveness of sphingosine-1
phosphate receptor 5 (S1P5) to its ligand (S1P) play a key role in
allowing NK cell egress via lymphatics (27). However, whether
this mechanism might also be effective in human has not yet
been confirmed. Notably, NK cells have been detected in efferent
lymph fluid and NK cells exiting from LN have a phenotype
slightly different from that of NK cells found within SLTs. In
particular, a portion of NK cells express significant amounts of
KIR and CD16, implying that CD56bright NK cells might acquire
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these molecules in the LN during inflammation and then egress
through the efferent lymph for recirculating in PB (28).
All these previous studies have so far depicted the distribution
of the twomain “conventional” human NK cell subsets across the
human body (8, 29). Recently, this issue reached a higher level of
complexity because of data showing that various body districts
harbor “unconventional” subsets of NK cells that apparently do
not recirculate in the blood or lymphatics and adopt a unique
phenotype that is distinct from that of circulating NK cells. Tissue
residency has been described for NK cells as well as for other
“helper” innate lymphoid cells (ILCs), T cell subsets (memory
CD8, CD4 and Treg cells) and “innate-like” T cell types, including
subpopulations of γ/δ T cells and natural killer T (NKT) cells
(30). Tissutal NK cells, similarly to other lymphocytes residing
in tissues, may display markers such as CD69, CD103 (also
known as αE integrin) and CD49a (also known as α1 integrin),
which are functionally involved in retaining them in tissues and,
hence, can be useful for the identification and isolation of tissue-
resident (tr) NK cells (Figure 1). As discussed earlier, at least
three-quarters of NK cells in non-reactive lymph nodes display
a CD56bright Perflow phenotype (20, 31). This accumulation is
compatible with the pattern of adhesion molecules (CD62L)
and chemokine receptors (CCR7) expressed on circulating PB-
CD56bright NK cells but not PB-CD56dim NK cells. From recent
data, it is possible to speculate that a fraction of NK cells reaching
the LN could be retained within the structure as trNK cells.
Supporting this hypothesis is the presence of a distinct subset of
NK cells in human SLTs characterized by co-expression of CD69
and CXCR6, high expression of CD54 (ICAM-1) but lacking
CD117 (c-kit) and CD127, the latter specifically expressed by
CD56bright NK cells (32). Because of the high level of CD54,
these SLT-NK cells are also reminiscent of CD56bright NKG2Apos
CD94pos CD54pos CD62Lneg NK cells that accumulate in tonsils
of EBV carriers, which produce high amount of IFNγ, show very
low plasticity even after prolonged cytokine stimulation, and are
able to potently restrict EBV-induced transformation of B cells
(33).
Among solid tissues, liver is abundantly populated by NK
cells, where they represent up to 30–40% of all the lymphocytes
populating this organ (34). At steady-state, NK cells are
preferentially located in the hepatic sinusoids, often adhering
to the endothelial cells (35). Similar proportion of CD56dim
and CD56bright NK cell populations have been reported to
populate this organ (36), but only CD56bright has been described
to own features of trNK cells. Indeed, liver CD56bright NK
cells are characterized by higher level of EOMES transcription
factor, expression of CXCR6 and CD69 as well as CCR5 but
absence of CD62L and CCR7 (37). Interestingly, the expression
of CD49e (also known as α5 integrin or VLA-5 α chain) has
been recently identified has a reliable marker able to distinguish
conventional “circulating” NK cells from bona fide liver-NK cells,
which are otherwise negative for this marker (38). Many reports
have suggested the importance of CCR5 and CXCR6 in their
localization and retention within liver parenchyma, since their
cognate ligands (CCL3, CCL5, and CXCL16) are constitutively
expressed by various parenchymal and non-parenchymal cells in
the liver, including cholangiocytes, sinusoidal endothelial cells,
hepatocytes and Kupffer cells (34). Investigation of human liver
transplants has indicated that EOMEShigh trNK cells can persist
in situ for very long periods (up to 13 years in one human
study), further supporting the idea that subsets of NK cells may
stably reside within liver tissues. At the same time, circulating
CD56bright EOMESlow cells may be recruited to the liver and have
the potential to become CD56bright EOMEShigh NK cells (39).
An exception to the aforementioned tissues is represented
by lungs since: (i) the majority (∼80%) of NK cells populating
these organs belongs to the CD56dim Perfhigh subset (40); (ii)
only a limited fraction of Lung-NK cells is characterized by
expression of markers consistent with tissue-residency (i.e.,
CD69). Interestingly, this fraction is mainly composed of
CD56bright CD16neg and only a small proportion of CD56dim
CD16bright NK cells (41), thus suggesting that “genuine” lung-
resident NK cells may share some commonalities with CD56bright
trNK cells found in the uterus, liver, and lymphoid tissues (37).
Lung-NK cells were detected in the parenchyma only, and were
not found outside of the parenchyma, (i.e., blood vessels or
bronchi) (8, 41). Therefore, overall, these data support a model in
which human lungs mainly contain highly differentiated NK cells
recirculating between lung and blood, rather than a stable pool
of tissue-resident NK cells (41). Consistent with this hypothesis,
using a parabiotic mouse model, it has been recently shown that
parabiont-derived donor NK cells are able to rapidly replenish
the majority of NK cells in the lungs of recipient mouse (42).
Development of tissue-resident lymphocytes seems to involve
a transcription program inducing the expression of genes
involved in tissue-retention while inhibiting that of genes
important for tissue egress and trafficking. In mice, it was
recently described that the transcription factor Hobit (homolog
of Blimp-1 in T cells or ZNF683), a zinc finger protein, acts
in concert with Blimp-1 (B lymphocytes-induced maturation
protein) to serve as a master regulator of tissue-residency for
lymphocytes. Thus, Hobit and Blimp-1 mediate a common
transcriptional program that is shared among tr memory (Trm)
T cells, NKT, trNK cells, and helper-like ILCs. Together with
Blimp-1, Hobit sustain unresponsiveness to signals for SLT re-
circulation from peripheral tissues by suppressing expression
of S1pr1 (which encodes S1P1), Sell (which encodes CD62L)
and Ccr7 (which encodes CCR7) (30). The role of Hobit in
human Trm cells is less clear. Recent reports have shown peculiar
results with regard to the expression of Hobit/ZNF683 in the
two major human PB-NK cell subsets. Indeed, Hobit has been
detected at high levels in circulating CD56dimNK cells (despite
this transcription factor is almost absent in circulating NK cells
in mice) while only poorly expressed by PB-CD56bright NK
cells (43, 44).
However, it has been found that a strong Hobit/ZNF683
expression identifies a subset of intrahepatic CD56bright NK
cells in human liver, which additionally express a distinct set of
adhesion molecules (CD69, CD49a) and chemokine receptors
(CXCR6) consistent with tissue residency (44). These data may
suggest that Hobit expression in humans may instruct unique
migratory properties in the two distinct circulating NK cell
subsets. Whilst low expression of Hobit in circulating CD56bright
NK cells could maintain high levels of CCR7 and CD62L
Frontiers in Immunology | www.frontiersin.org 4 October 2018 | Volume 9 | Article 2324
Castriconi et al. Trafficking of Human NK Cells
necessary for SLT entry, high level of Hobit in CD56dim and
CD56bright trNK cells might down-regulate these markers on
their surface, thus limiting their recirculation to SLT and tissue
egress, respectively.
NK CELLS IN PREGNANCY
Pregnancy is a quite peculiar situation, in which an
immunocompetent individual (the mother) is in contact for a
long period of time with a genetically different immunodeficient
individual (the fetus), and is characterized by a deepmodification
of mother’s tissues. During the first trimester of pregnancy,
extravillous trophoblast cells (EVT) from the fetus invade the
maternal decidua penetrating through the basement membrane
of the uterus epithelium with remodeling of the maternal spiral
arteries. These changes ensure adequate nutrition of the fetus
and are supported by immune cells present at the maternal-fetal
interface (45). In normal pregnancy many different mechanisms
exist to ensure tolerance of the semi-allogeneic fetus by the
maternal immune defense, thus preventing fetus rejection and
allowing the reproductive success.
The decidua is populated by a large variety of leukocytes,
which represent approximately 30–40% of decidual cells. The
most represented leukocyte populations are NK cells, CD14pos
myelomonocytic cells and T lymphocytes (46). Decidual NK
cells (dNK) represent 50–90% of total decidual lymphoid cells
in the first trimester of pregnancy (47) (Figure 1). The number
dwindles by the end of second trimester, and returns to basal
levels at the end of pregnancy. NK cells have also been identified
in non-pregnant endometrium (eNK) and their number changes
throughout the menstrual cycle, reaching the maximal level in
the post-ovulatory phase of the cycle (48). Most uterine NK
cells do not express CD16 and show high levels of CD56.
The dNK cells have been shown to exhibit unique phenotypic
and functional properties. Indeed, relevant differences exist
in the gene expression of the NK cell subsets present in
peripheral blood and early pregnancy decidual tissues. CD9
tetraspanin, galectin, α-1 integrin and other adhesion molecules
are overexpressed in dNK (49). Unlike resting PB NK cells,
dNK cells express the CD69 marker and a large percentage
express the NKp44 activating receptor. The expression levels
of activating receptors/co-receptors (NKp46, NKp30, DNAM-
1, NKG2D, and 2B4) are similar in dNK and PB NK cells
and, regarding to inhibitory MHC class I-specific receptors, the
dNK cells have been shown to express Killer Immunoglobulin
receptor (KIRs), CD94/NKG2A and LILRB1 (also known as
ILT2, LIR1, and CD85j). Interestingly, the KIR repertoire of
dNK cells is skewed toward recognition of HLA-C, the only
classical MHC Class I molecule expressed by trophoblast cells
(46, 50). Although expressing both perforin and granzymes
dNK cells are poorly cytotoxic, a characteristic that has been
linked to the block in the polarization of cytolytic granules
to the immunological synapse (51). Importantly, cytokines,
such as IL-15 can restore the dNK cell cytotoxic function, a
phenomenon that is crucial in normal pregnancy to control viral
infection (52).
Various studies have shown peculiar functional capabilities
of dNK cells. Indeed, they release a wide panel of cytokines,
chemokines, and angiogenic factors that are involved in
the development of placenta, tissue remodeling, trophoblast
invasion and neoangiogenesis (48). Several studies analyzed the
chemokine repertoire in endometrium and decidual tissues of
women undergoing elective pregnancy termination, studying
its involvement in NK recruitment. CXCL9 (Mig), CXCL10
(IP10), CXCL12 (SDF-1), CCL3 (MIP-1α) e CCL4 (MIP-1β)
are constitutively expressed in the endometrium. First-trimester
human trophoblast expressed and released chemokines able
to exert their activity on NK cells, including CXCL12 and
CCL3 (53). In line with these results studies have shown that
chemokines produced by endometrial or trophoblast cells induce
the peripheral blood NK cell chemotactic response. Decidual
endothelial and stromal cells express CCL2 (MCP-1), CXCL8
(IL-8), CXCL10, CX3CL1 (fractalkine), and CXCL12 while only
stromal cells express detectable levels of CCL5 (Rantes) and
CCL4. Noteworthy, CXCL10, CXCL12 and CX3CL1 induce the
migration of PB NK cell across primary cultures of decidual
endothelial and stromal cells (54). Furthermore it has been shown
that also chemerin is expressed in the uterus by EVT and stromal
cells but not by decidual endothelial cells (DEC) (55–58). The
treatment of DECs and stromal cells with progesterone enhanced
CXCL10, CX3CL1, and CCL2 but not CXCL12 levels, while
estrogen treatment of stromal cells resulted in up-regulation
of CXCL10 and CX3CL1 (54–57). Moreover, the treatment
of stromal cell primary cultures from pregnant, fertile non-
pregnant, or menopausal women with progesterone and estrogen
resulted in a significant up-regulation of chemerin secretion.
Although it is unclear how and when the various chemokines
participate in the recruitment of dNK cells, it has been shown
that dNK cells express high levels of CXCR3, low level of CXCR4
and very low levels of CXCR1, CXCR2, CX3CR1 or CCR1, 2, 3,
5, 6, and 7. In this regard, CXCR3 and CXCR4 are involved in
migration of decidual NK cells to CXCL9, CXCL10 and CXCL12
respectively (59). Moreover dNK cells migrate through stromal
cells in response to CXCL10 and CXCL12 but not to CX3CR1
(54). Interestingly, dNK cells from pregnant women express
chemerin receptor (ChemR23 or CMKLR1) that induces their
migration through stromal cells in response to chemerin. The
different chemokine receptor profile between dNK and PB NK
cells suggests that the phenotypic features of leukocytes recruited
from peripheral blood during pregnancy can be influenced by the
decidual microenvironment. In this regard, evidence indicates
that the pregnant uterus is a good source of cytokines acting
on NK cells including IL-15 (60). Interestingly in vitro culturing
of PB NK cell with IL-2 or IL-15 induced a down-regulation
of ChemR23 (18). In line with these observations studies have
shown that co-culture of PB NK cells with stromal cells results
in a chemokine receptor profile similar to that of decidual NK
cells (54).
Nevertheless, it is noteworthy that the precise origin of dNK
cells is not yet clear. It is possible to speculate that a pool of
dNK cells may originate from PB NK cells recruited in decidua
at early stages of pregnancy. On the other hand, studies suggest
that they could also originate from in situ progenitor cells that,
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in response to uterine stromal environment, differentiate into
CD56bright CD16neg NK cells (61).
NK CELLS IN TUMOR TISSUES
A consolidated view considers NK cells as the more effective
lymphocyte subset involved in immune surveillance of
hematological malignancies, initial stages of solid tumors
and blood spreading metastatic cells (62–64). Conversely,
NK cells appear to be poorly efficient in controlling advanced,
consolidated tumors due to different reasons, which comprise the
plethora of immune suppressive factors characterizing the tumor
microenvironment (63, 65). These include the expression by
cancer cells of MHC class I molecules and immune checkpoint-
ligands such as PD-Ls and B7-H3 (63, 66), the lack of expression
or the release of soluble forms of ligands of activating receptors,
and the presence of soluble immunomodulators, the prototypic
one being represented by TGF-β1 (63, 65). Additional aspects
impacting on the NK-mediated tumor immune surveillance
are the low frequency and/or the quality of NK cells attracted
in tumor tissues (Figure 2). Indeed, highly cytolytic CD56dim
CD16pos NK cells are rare and immature CD56bright CD16low/neg
NK cells with low perforin content represent the majority of
tumor-associated NK cells. Although some authors suggested
the possibility of an in situ expansion of CD56bright NK cells
(67), a shared hypothesis considers as primum movens the type
of chemokines/receptors interactions occurring in the tumor
microenvironment.
The tumor orchestrates escape strategies and creates a
chemokine milieu consisting of reduced expression of CXCL2,
CX3CL1, CXCL1, and CXCL8, attracting CD56
dim NK cells,
and increased expression of CXCL9, CXCL10, CXCL19, and
CCL5 that drives migration of CD56bright NK cells. The
dichotomy between high (CD56dim) and low (CD56bright)
cytolytic NK cells has been widely studied and data show that
pro-inflammatory cytokines can increase the killing properties
of CD56bright NK cells (68). However, this cytokine-mediated
rescue mechanism might be deeply affected by TGF-β (69),
which is highly represented in tumor tissues. This is because
the tumor environment is rich in both TGFβ-1 producing cells
and in factors that induce TGFβ activation, such as acidic
pH, reactive oxygen species, proteases and specific members of
integrin family (70). Active TGF-β1 decreases the expression
of activating NK receptors and, by up-regulating mir27a-5p,
of perforin 1 (Prf1) and granzyme B (GzmB), thus hampering
NK cell cytotoxicity. Moreover, TGF-β1 might dampen CD56dim
recruitment and favor that of CD56bright by modifying their
respective chemokine receptor repertoires (13). In particular,
TGF-β1 increases the expression of CXCR3 and CXCR4 in
CD56brigh and CD56dim NK cells, whereas, via mir27a-5p,
down-regulates CX3CR1 expression in CD56
dim cells (13, 71).
CX3CR1, whose cognate ligand is represented by CX3CL1 (also
known as fractalkine), is selectively expressed by CD56dim NK
cells and together with CXCR4 has been demonstrated to regulate
NK cell-egress from bonemarrow andNK cell extravasation (72).
Interestingly, in agreement with this ability of tumors in inducing
a regulatory milieu, an unusual low expression of CX3CR1
has been reported in CD56dim NK cell population of tumor-
infiltrated bone marrow and peripheral blood of Neuroblastoma
(NB) patients (13). Although a more detailed analysis should be
performed to deepen whether this unusual chemokine receptor
repertoire actually defines a peculiar CD56dim population (73)
mirroring the “broad spectrum of human Natural Killer Cell
Diversity” (2), it is conceivable that CX3CR1
low CD56dim cells
show defective migration toward tumor (or inflamed tissues).
Conversely, the recruitment of CD56bright NK cells in a CXCL9
and CXCL10 rich milieu might be favored by their constitutive
expression of high levels of CXCR3 and CXCR4, which further
increase under the influence of TGFβ-1 (8, 16, 17). Along this
line, CD56bright CD16low represented the predominant NK cell
population in the ascitic fluids of ovarian cancer patients (74).
The concomitant up-regulation of CXCR3 and CXCR4 by TGF-
β1 represents an interesting event if considering that these
receptors are subject to cross regulation. Indeed, chemokine
receptors’ function can be modulated by desensitization, which
is a physiological process that prevents overstimulation due to
prolonged agonist exposure by signal attenuation or termination
(27). Desensitization of a receptor can be dependent on
its ligand (homologous desensitization) or by other ligands
present in a complex chemokine gradient, a cross-desensitization
called heterologous desensitization. In this context it has been
shown that pre-stimulation of NK cells with CXCL9 inhibited
NK cell migration not only to CXCR3 ligands but also to
CXCL12, thus indicating that triggering of CXCR3 can promote
both homologous and heterologous (CXCR4) desensitization
(75).
In solid tumors a “fast track entrance” for CD56bright
CX3CR1
neg CXCR3high CXCR4high NK cells might be the ectopic,
neo-generated High Endothelia Venules (HEV) that contribute
to the architecture of Tertiary Lymphoid Structures (TLS)
(76, 77). These transient, un-capsulated lymphoid aggregates
resembling Secondary Lymphoid Organs (SLO) have been
detected in peri- or intra-tumor sites as well as in other chronic
inflamed tissues. TLS share with SLO the presence of distinct
T and B cell compartments, reactive Germinal Center (GC),
Follicular Dendritic Cells (FDC), fibroblastic reticular cells (FRC)
and lymphatic vessels, as well as HEV whose lining endothelial
cells express highly specific addressin molecules, collectively
termed peripheral node addressins (PNAd) (76). These are
known to dictate adhesion and consequent extravasation of
immune cells, including NK cells, within paracortical region
of lymph nodes, an event that might occur also at TLS levels.
In different tumors including lung, breast or gastrointestinal
stromal tumors (GIST) (78), tumor-associated TLS might
contribute to the preferential recruitment of CD56bright NK cells
that constitutively express the homing receptor CD62L and high
levels of CCR7 specific for the lymph node chemoattractants
CCL19 and CCL21. For example, in TLS associated to human
lung cancer intra-tumoral PNAd+ HEV exclusively co-localized
with CD62L+ lymphocytes (76). Notably, while TGF-β negatively
impacts on CD56dim NK cells recruitment in perturbed tumor
tissues, upregulation of CCR7 may promote their migration to
SLO and TLS. Accordingly, enrichment in CD56dim CCR7+
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FIGURE 2 | NK cells in tumor microenvironment. The tumor chemokine milieu presents a reduced expression of chemokines attracting CD56dim NK cells, and an
increased expression of CXCL9/10, CCL5, and CXCL19/21 that drives the migration of CD56bright NK cells toward the stromal compartment and tertiary lymphoid
tissue (TLS). Tumor cells and tumor-associated macrophages (TAM) release/activate TGF-β1 that decreases the capability of NK cells to recognize and kill targets and
modify their chemokine receptor repertoire, hampering the recruitment of CD56dim NK cells and favoring that of poor cytolytic CD56bright. ActR, Activating
receptors; GzmB, Granzyme B.
KIR+ CD57+ highly cytotoxic NK cells has been documented
in tumor-infiltrated lymph nodes of melanoma patients (79).
Several mechanisms involved in the acquisition of CCR7 by
CD56dim NK cells have been identified that include the crucial
role of IL-18, highlighted by Mailliard et al. (80), and the possible
uptake of CCR7 from surrounding cells by trogocytosis (81).
Soluble IL-18 is produced by stimulated antigen presenting cells,
in particular by macrophages that, as M2-polarized cells, might
represent the most abundant immune population in the tumor
microenvironment (82). Interestingly, a variable subset (30–40%)
of unpolarized (M0) and M2 macrophages and most tumors
associated macrophages (TAM) express a membrane form of IL-
18 (mIL-18) (74, 83, 84). Upon TLR stimulation, macrophages
polarize toward M1 and loose mIL-18, an event paralleled by the
release of small amounts of soluble IL-18 (sIL-18) that, acting in
close proximity, induces the expression of CCR7 in CD56dim NK
cells (83). It is of note that, since M1 polarizing macrophages also
acquire CCR7 expression (83), a contribution of trogocytosis-
mediated uptake cannot be ruled out. Although mechanisms
responsible for IL-18 membrane retention and release have
to be clarified, this cytokine shows many predictable cleavage
sites for extracellular proteases such as Matrix metallopeptidase
(MMP) −2 and −9, which characterize the secretory profile of
parenchymal tumor cells and TAM. Thus, also in the absence
of pathogen-derived stimuli, the action of MMPs (or other still
unknown mechanisms), may allow IL-18 shedding from TAM
and the induction of CCR7 expression in CD56dim tumor-
associated NK cells (TA-NK), thus promoting their migration to
SLO and TLS.
In solid tumors CCR7 acquisition by NK cells may depend
on close cell-to-cell contacts with macrophages or dendritic
cells, whereas it is less plausible that tumor cells could
play a relevant role. Indeed, TA-NK cells were found to be
predominantly located in the stromal compartment, whereas
they were rare/absent in the parenchyma in direct contact
with tumor cells (40, 85). Regarding the compartmentalization
of TA-NK cells, in an adenocarcinoma colon model, stromal-
infiltrating NK cells had morphology compatible with actively
migrating cells, and in some instances migrating NK cells
co-localized with degraded matrix (85). In the same model,
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most of the NK-poor tumor nodules were surrounded by a
capsule-like structure with collagen IV and laminin, two major
components of the basement membrane. On the contrary,
tumor nodules lacking these containment structures were more
infiltrated by NK cells. These observations, together with data
showing that poor NK cells infiltration have been equally
detected in both chemokines-rich and -poor tumors, strongly
indicate stromal barriers as a hindrance impacting on possible
NK-to-tumor cell contacts. Along this line, during imatinib
mesylate therapy in GIST patients, the frequency of NK cells
did not change in fibrous trabeculae, whereas significantly
increased in the core of both localized or metastatic tumors,
an observation that correlated with a better prognosis (78).
Interestingly, a recent study analyzing the off-target effect of
imatinib mesylate on immune cells showed that this drug causes
a significant up-regulation of CXCR4 in both T and NK cells
(86). Accordingly, NK cells ex-vivo isolated from peripheral
blood of chronic myeloid leukemia patients receiving imatinib
mesylate showed levels of CXCR4 significantly higher than those
detected in healthy individuals (86). A study by Goda S. and
colleagues (87)may in part explain how increased CXCR4 surface
levels can facilitate NK cells to cross the bridge connecting
the stroma and the tumor parenchyma compartments. In
particular, they showed that human CD56dim CD16pos NK
cell invasion into type I collagen is enhanced by CXCL12,
the CXCR4 ligand, in a matrix metalloproteinases (MMP)-
dependent manner. Notably, CXCL12 has been shown also to
promote the production in monocytes (88) and megakariocytes
(89) of MMP-9, which has protease activity on collagen IV. With
this assumption, it is conceivable that therapies strengthening
the CXCR4/CXCL12 axis could potentiate extracellular matrix
degradation favoring NK (and T) cells migration toward tumor
cells.
In light of these considerations, data on the NK cell phenotype
and density in tumor sites cannot be considered “per se” a
favorable prognostic factor and should be more and more
integrated with data on NK cell localization with respect to
stroma, parenchyma tumor cells and with the analysis of the
whole immune landscape. For instance, high NK cell infiltration
has been associated with improved survival in metastastic
renal cell carcinoma but not in colorectal carcinoma (90).
Contradictory results may depend on the method used to
unequivocally identify NK cells, which still represents a major
challenge as NKp46, the more reliable marker, is also expressed
by other subsets of ILCs (91). Opposite clinical impact of
NK cell infiltration in solid tumors might also depend on the
targeted tissue, the tumor phase and the ratio between NK
and tumor cell numbers. It has been demonstrated that NK
cells can edit tumor cells modifying their immunogenicity. In
particular, in NK and melanoma cell co-cultures performed
at low effector/target ratios, which reflect the level of NK
cell infiltrates observed at the tumor site, an initial tumor
cell lysis is followed by an equilibrium phase characterized
by decreased susceptibility to killing due to up-regulation of
both classical and non-classical MHC class I molecules on
melanoma cells. This effect is mediated by IFN-γ released by
NK cells activated upon melanoma cell recognition. Importantly
IFN-γ and TNF-α are also potent inducers of the expression
of the immune checkpoint ligands PD-L1 and PD-L2 in
macrophages/dendritic cells, tumor cells and tumor-associated
endothelial cells (92, 93). Moreover, TNF-α is known to promote
Epithelial-Mesenchymal Transition (EMT), a process leading
epithelial tumors to acquire a less differentiated, pro-metastatic
phenotype. Along this line, in lung cancer, a recent report
showed an important correlation between PD-L1 expression and
EMT score (93, 94). Thus, low number of NK cells contacting
tumor cells might have more undesirable than beneficial effects,
being unable to efficiently eliminate tumor cells while causing a
gradual accumulation of cytokines that exert a paradoxical tumor
promoting effect by modifying the immunogenicity of tumor
cells.
Whatever the case, when designing NK cell-based
immunotherapeutic approaches for cancer patients, we should
take into account the relevance of the molecular mechanisms
regulating NK cell migration into tumors. For instance, a recent
and promising approach is represented by the infusion of NK
cells engineered to express chimeric antigen receptor (CAR)
specific for tumor-associated antigens (65, 95, 96). The efficacy
of adoptively transferred CAR-NK might be deeply limited
by their inability to cross stromal barriers and to adhere to
parenchymal tumor cells, as recently suggested for T cells by
Caruana and colleagues (97). It was pointed out that in vitro
manipulation aimed to the CAR engineering of T cells leads
to silencing of heparanase (HPSE), an endoglycosidase that
cleave heparan sulfate proteoglycans of ECM, thus reducing
the invasive potential of CAR-T cells in solid tumors. Thus,
cell-based therapy may also include strategies to favor migration
of effector cells through stromal compartment and tumor
parenchyma, a phenomenon unlikely to occur, particularly in
advanced solid tumors.
NK CELLS IN INFLAMED TISSUES
The perturbation mediated by pathogens in peripheral tissues
results in the early activation of resident or recruited cells of
the innate immunity with a consequent boost of chemotactic
factors, which attract different immune cells including peripheral
blood mature conventional CD56dim NK cells. These cells
mainly differentiate in the bone marrow and express CXCR1,
CXCR2, chemR23, S1P5, CXCR4, and CX3CR1 (16, 17, 26).
This chemokine receptor repertoire drives NK cells to inflamed
tissues. Importantly, the relative expression of CXCR4 and S1P5
in developingmouse NK cells has been described to regulate bone
marrow egress into circulation (98). Moreover, in bone marrow,
prevalent CX3CR1 expression by KLRG1
+ NK cells located in
sinusoids suggested its crucial role for NK cell entry into the
vascular compartment (99).
The presence of NK cells in healthy and inflamed peripheral
tissues (18, 26, 29) has been well documented and different
studies demonstrated the existence of a crucial crosstalk between
CD56dim NK cells and DC or macrophages (Figure 3). NK/DC
interactions resulted in a bidirectional activation leading to
killing of immature DC (iDC) by autologous NKG2A+ KIRneg
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FIGURE 3 | NK cells in inflamed tissues. Inflamed tissue produce chemokines (Chemerin, CX3CL1) that drive the migration of circulating CD56dim prf1high NK cells.
Once in tissues they interact with DC and macrophages that, upon pathogen recognition, have begun to mature (mDC) or polarize toward a proinflammatory
functional phenotype (M1). Maturing DC and M1-polarizing macrophages release immunostimulatory cytokines that induce NK cells to produce large amounts of
IFN-γ (which potentiate phagocytes’ functions) and to express IL-2Rα and CCR7, which drive their migration into secondary lymphoid organs (SLO). mDC migrated to
SLO and DC-primed T cells producing IL-2 stimulate CD56dim NK cells and CD56bright NK cells that acquire a CD16pos KIRpos phenotype. ActR-L, Activating
receptors ligands; iNKRs, MHC class I specific inhibitory receptors (KIRs, CD94/NKG2A); Chem, chemerin.
NK cells. NK-mediated DC lysis, due to a pivotal role of NKp30
and DNAM-1 activating receptors (20, 100), is restricted to iDC
undergoing an unfruitful maturation process, characterized by an
inadequate MHC class I up-regulation. This mainly impacts on
the expression of the non-classical HLA-E molecule, the cognate
ligand of the CD94/NKG2A inhibitory receptor. This effect has
been interpreted as a negative selection strategy aimed to avoid
inappropriate antigen presentation by MHC class I low DCs,
which could result in tolerogenic responses. DC that underwent
an appropriate maturation program (mature dendritic cells,
mDC) are spared from NK-cell mediated attack since they
express very high levels of classical MHC class I and significantly
up-regulated HLA-E (101, 102). The principal NK cell-derived
mediators shaping DC immune-phenotype are represented by
TNFα and IFNγ, whose release depends on the synergistic
activity of IL-12 and IL-15 produced by pathogen stimulated
DC. mDC de novo express CCR7, (a phenomenon also occurring
during pathogen-driven macrophage polarization toward M1)
which confers to these cells the competence for migrating to SLO.
In SLO T cell zone, DCs co-localize with NK cells belonging to
the CD56bright CD16low/neg subset, which constitutively express
CCR7 (101).
The complex interactions among NK cells expressing IL-
2Rα (CD25), DC-primed T cells producing IL-2 and mDC
result in a conspicuous IFN-γ production by NK cells shaping
T cell priming, polarization and adaptive immune responses
(101). Whether, in SLO, NK cells may also shape macrophages’
functions remains to be elucidated. CCR7pos. NK cells can
migrate to SLO via HEV since they also express high levels
of CD62L. However, a predominant population of CCR7pos
CD56bright CD16neg NK cells has been described in seroma
fluid, thus depicting afferent lymph as an alternative way
for CD56bright NK cells to colonize SLO (8). Interestingly, it
has been observed, in seroma, the presence of low numbers
of CD56posCD3neg cells expressing CX3CR1, KIRs and CD16
molecules, a phenotype usually characterizing classical CD56dim
NK cells (8). Although a multiparametric analysis providing
information about a possible co-expression of CCR7 was lacking,
these data support the hypothesis that, in vivo, cytolytic CD56dim
NK cells might also migrate to “perturbed” SLO. Along this line,
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the interaction of CD56dim NK cells withM0 orM2macrophages
polarizing toward M1 upon TLR engagement results in the
acquisition of CCR7 and of a fully activated NK cell status
characterized by high CD69 and IL2Rα expression, release of
large amount of IFN-γ and increased cytolytic activity (83). Thus,
in inflammatory conditions, M1-activated CD56dim NK cells,
becoming competent for SLOmigration thanks to the acquisition
of CCR7, might deeply contribute to both immunosurveillance
of tumor metastases and control of infected cells. Migration of
fully functional CD56dim NK cells to SLO, could be particularly
relevant in the context of KIR/KIRL-mismatched haploidentical
stem cell transplantations (haplo-HSCT). Indeed, in SLO, NK-
mediated killing of recipient mDC and residual T cells might
contribute to the low rate of graft vs. host disease (GVHD) and
graft rejection documented in this clinical setting (103).
Nevertheless, is there any in vivo evidence that CD56dim NK
cells might traffic through and leave SLO, thus recirculating
via efferent lymph? A few preliminary reports indicate
this possibility. Non-reactive LNs or LNs characterized
by sinus hyperplasia lack or show low expression of
KIRposCD16pos cells. Interestingly, reactive LNs characterized by
paracortical/follicular hyperplasia harbor a significant percentage
of cells expressing KIR and CD16 and a similar KIRposCD16pos
cells enrichment was observed in the efferent lymph (i.e.,
toracic duct). Several observations, including a difference in the
telomerase length, strongly suggest that CD56bright CD16neg
KIRneg cells can acquire a KIRpos CD16pos phenotype thanks to
the influence of the different pro-inflammatory cytokines present
in LNs (28). However, the hypothesis that CD16pos KIRpos
NK cells might migrate to and expand in LNs before egressing
via efferent lymph cannot be ruled out. In this context, in
pathogen-perturbed tissues, CD56dim NK cells interacting with
macrophages acquire the competence to SLO migration and,
expressing high levels of IL2Rα (83), become highly responsive
to IL-2 produced by T cells in the paracortex area of LN.
Pro-inflammatory cytokines are capable of shaping innate and
adaptive immune responses also acting on the establishment
of the NK cell memory reservoir. Both in mouse and human,
it has been described that the CMV-driven onset of memory
NK cell populations requires the presence of pro-inflammatory
cytokines such as IL-12 and IL-18. Cytokines represent the
third signal essential to generate, expand and recall NK cell
memory. Signal 1 is represented by receptor-mediated antigen
recognition, LY49D in mouse and NKG2C or KIR2DS1 in
humans, and signal 2 by co-stimulatory signals, DNAM-1 and
CD2 in mouse and human, respectively (15, 104). In addition,
cytokines by themselves are capable of generating memory-
like NK cells in an antigen–independent setting (14), as NK
cells, shortly cultured in the presence of IL-12, IL-15 and IL-18,
showed superior IFN-γ and TNF-α production and cytotoxicity
in response to tumor targets and conferred more protection
to leukemia or melanoma in xenograft mouse models. Thus,
full NK cell activation and antigen-dependent or -independent
generation of NK cell memory requires cytokines-mediated
signals. It should be considered that cytokines also strongly
impact on the chemokine receptor repertoire of NK cells.
Beside sIL-18 whose capability of inducing CCR7 expression
has been discussed above, IL-15 has been shown to down-
regulate CX3CR1 expression in mouse bone marrow-derived NK
cells (10) and in human PB NK cells (12), thus reducing the
chemotactic response to CX3CL1 ligand (12). IL-12 in association
with IL-2 significantly decreased the CXCR3 mRNA and their
surface expression in NK cells (9). Additionally, IL-2 alone has
been shown to down-regulate the surface expression of CXCR1
as well as of CXCR4 inhibiting NK cell migration in response
to CXCL12. On the other hand, IL-2 up-regulated the surface
expression of CXCR3 increasing NK cell migration in response
to its ligands CXCL9 and CXCL10 (11).
Regarding the migratory properties of memory NK cells,
different questions remain unanswered. Do cytokines that drive
their onset, impact on their chemokine receptor repertoire
contributing to the generation of tissue-resident memory NK
cells in various anatomical areas? Does the maintenance of
the NK cell memory pool involve tissue-restricted reactivation
of resident memory NK cells or do these cells maintain the
potential to recirculate? Studies focused onmouse recall response
to haptens provided some relevant indications. These studies
showed that memory NK cells responsible for the immune
response were the CD49a+ DX5neg liver resident NK cells, and
that the activity of CD18 and P-selectin, molecules involved
in trafficking of NK cells, was needed (15). In this scenario,
the characterization of human memory NK cells in terms
of chemokine receptor expression, before and after cytokine-
stimulation, could be particularly relevant.
CONCLUDING REMARKS
It has become evident that NK cells are not constituted by a
homogeneous population of innate lymphocytes but rather by
different subtypes with specific abilities as well as distinct homing
properties. Investigating howNK cell subsets distribute in human
body has relevance not only for a better understanding of our
immune defenses but also for exploiting these cytotoxic cells in
therapeutic settings.
It is worth noting that the migratory properties of NK
cell subsets are relevant not only for identifying the region
in which they should exert their activity. Recent reports
indicate that NK cells could acquire specific properties, such as
cytotoxicity, only upon their migration to secondary lymphoid
organs where the cytokine milieu would induce their further
differentiation. At the same time, although the picture of tissue-
resident NK cells is still fuzzy, it is conceivable that these
subsets of NK cells might locally acquire peculiar properties,
such as release of specific soluble factors able to affect
their properties but also influence other cells present in the
microenvironment. As a matter of fact, NK cells (as well as
all other innate lymphoid cells of which they represent the
prototype) are more and more emerging as accessory cells
able to modulate the functions of neighboring cells, including
antigen presenting cells, in the environment in which they are
attracted/hosted.
Despite the relevance of these issues, several open questions
still remain to be addressed regarding the ability of NK cells
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to infiltrate and reside in either healthy or pathological tissues.
Decades after the discovery of NK cells as lymphocytes able
to recognize and kill cancer cells without prior sensitization
to them, we still miss a clear and complete depiction of
the phenotype and properties of tumor-infiltrating NK cells.
Similarly, although a number of studies have now highlighted
the relevance of NK cells in the control of viral infections, how
these cytotoxic lymphocytes recirculate and/or are retained in
infected tissues still remain to be clearly determined, at least in
humans.
On the other hand, novel technologies allowing extensive
multiparametric analyses, either by mass cytometry or classical
flow cytometry, not even conceivable until only a few years ago,
might now open new avenues for a comprehensive mapping of
tissutal NK cells. The path appears already tracked since we have
now, as reported in the present review, a better appreciation of at
least some of the molecules and the signaling ruling the homing
properties of these innate lymphocytes.
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